Lymphoma

LYMPHOMA ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

COVID-19 Vaccination and Imaging Misinterpretation: An Interview With Lacey McIntosh, DO, MPH

Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making.
Patients Continue to Be Inadequately Informed of Risk for Breast Implant-Associated ALCL

Although the risk for breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) has been well-documented, patients considering breast implants continue to be inadequately informed of the propensity for disease development.
Bystander Killing Could Be Key Factor in CAR-T Success in Non-Hodgkin Lymphoma

Chimeric antigen receptor (CAR)-T cells can kill off-target tumor cells in the vicinity of the target cells, a phenomenon known as bystander killing. Modulating the expression of the protein mediating this process—Fas—could be a strategy to improve CAR-T efficacy.
Considerations for Secondary Primary Malignancy Development in Follicular Lymphoma

As follicular lymphoma (FL) survival rates have improved, concern that patients are at increased risk for the development of a secondary primary malignancy (SPM) has arisen.
Current Treatment Options for Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Investigators summarize current literature surrounding the treatment of NLPHL and discuss treatment considerations for 2 clinical cases.

VIDEO SERIES

HTLV-related Research in the United States

Mogamulizumab for HTLV-related Lymphoma

Tailoring Treatments

Specializing Care

LYMPHOMA NEWS

As oncologists welcome new chronic lymphocytic leukemia treatments, one researcher creates a scoring system to make the case for transplants.

AlloHCT Following Treatment With PD-1 mAbs Beneficial in Classic Hodgkin Lymphoma

April 9, 2021

Novel immunotherapies and small molecule pathway inhibitors are transforming the standard of care for some of the most challenging lymphoma subtypes.

R-MegaCHOEP vs R-CHOEP-14 in Newly Diagnosed Aggressive B-Cell Lymphoma

April 2, 2021

Aspirin

Low-Dose Aspirin Associated With Reduced Likelihood of Non-Hodgkin Lymphoma Diagnosis

March 31, 2021

Over half of evaluable patients who received an infusion of tisagenlecleucel achieved response.

Outcomes of PET4-Guided Omission of Radiotherapy Consolidation in Hodgkin Lymphoma

March 26, 2021

Micrograph of non-Hodgkin lymphoma

Adding Lenalidomide to R-CHOP Fails to Improve PFS in DLBCL Subtype

March 11, 2021

Next post in Lymphoma

Novel immunotherapies and small molecule pathway inhibitors are transforming the standard of care for some of the most challenging lymphoma subtypes.

R-MegaCHOEP vs R-CHOEP-14 in Newly Diagnosed Aggressive B-Cell Lymphoma